Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 6.03 USD -0.99% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
Recursion Pharmaceuticals Inc?
Write Note

Intrinsic Value

RXRX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RXRX stock under the Base Case scenario is 1.89 USD. Compared to the current market price of 6.03 USD, Recursion Pharmaceuticals Inc is Overvalued by 69%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RXRX Intrinsic Value
1.89 USD
Overvaluation 69%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Recursion Pharmaceuticals Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
RXRX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for RXRX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about RXRX?
Bearish
Neutral
Bullish

Fundamental Analysis

6.03 USD
-0.99%
-0.99%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Recursion Pharmaceuticals Inc
US
Biotechnology
Market Cap
2.3B USD
IPO
Apr 16, 2021
Employees
216
United States of America
Market Cap
2.3B USD
Industry
Biotechnology
IPO
Apr 16, 2021
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Recursion Pharmaceuticals Inc

Provide an overview of the primary business activities
of Recursion Pharmaceuticals Inc.

What unique competitive advantages
does Recursion Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Recursion Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Recursion Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Recursion Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Recursion Pharmaceuticals Inc.

Provide P/S
for Recursion Pharmaceuticals Inc.

Provide P/E
for Recursion Pharmaceuticals Inc.

Provide P/OCF
for Recursion Pharmaceuticals Inc.

Provide P/FCFE
for Recursion Pharmaceuticals Inc.

Provide P/B
for Recursion Pharmaceuticals Inc.

Provide EV/S
for Recursion Pharmaceuticals Inc.

Provide EV/GP
for Recursion Pharmaceuticals Inc.

Provide EV/EBITDA
for Recursion Pharmaceuticals Inc.

Provide EV/EBIT
for Recursion Pharmaceuticals Inc.

Provide EV/OCF
for Recursion Pharmaceuticals Inc.

Provide EV/FCFF
for Recursion Pharmaceuticals Inc.

Provide EV/IC
for Recursion Pharmaceuticals Inc.

Show me price targets
for Recursion Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Recursion Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Recursion Pharmaceuticals Inc?

What are the Net Income projections
for Recursion Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Recursion Pharmaceuticals Inc?

What are the EPS projections
for Recursion Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Recursion Pharmaceuticals Inc?

What are the EBIT projections
for Recursion Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Recursion Pharmaceuticals Inc?

Compare the revenue forecasts
for Recursion Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Recursion Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Recursion Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Recursion Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Recursion Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Recursion Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Recursion Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Recursion Pharmaceuticals Inc.

Provide ROE
for Recursion Pharmaceuticals Inc.

Provide ROA
for Recursion Pharmaceuticals Inc.

Provide ROIC
for Recursion Pharmaceuticals Inc.

Provide ROCE
for Recursion Pharmaceuticals Inc.

Provide Gross Margin
for Recursion Pharmaceuticals Inc.

Provide Operating Margin
for Recursion Pharmaceuticals Inc.

Provide Net Margin
for Recursion Pharmaceuticals Inc.

Provide FCF Margin
for Recursion Pharmaceuticals Inc.

Show all solvency ratios
for Recursion Pharmaceuticals Inc.

Provide D/E Ratio
for Recursion Pharmaceuticals Inc.

Provide D/A Ratio
for Recursion Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Recursion Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Recursion Pharmaceuticals Inc.

Provide Quick Ratio
for Recursion Pharmaceuticals Inc.

Provide Current Ratio
for Recursion Pharmaceuticals Inc.

Provide Cash Ratio
for Recursion Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Recursion Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Recursion Pharmaceuticals Inc?

What is the current Free Cash Flow
of Recursion Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Recursion Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Recursion Pharmaceuticals Inc

Current Assets 474.2m
Cash & Short-Term Investments 427.6m
Receivables 2.3m
Other Current Assets 44.3m
Non-Current Assets 252.3m
PP&E 159.2m
Intangibles 86.1m
Other Non-Current Assets 7m
Current Liabilities 108.9m
Accounts Payable 2.3m
Accrued Liabilities 48.8m
Other Current Liabilities 57.8m
Non-Current Liabilities 93.1m
Long-Term Debt 20.5m
Other Non-Current Liabilities 72.5m
Efficiency

Earnings Waterfall
Recursion Pharmaceuticals Inc

Revenue
65.2m USD
Cost of Revenue
-42.3m USD
Gross Profit
22.9m USD
Operating Expenses
-417m USD
Operating Income
-394.2m USD
Other Expenses
16.4m USD
Net Income
-377.8m USD

Free Cash Flow Analysis
Recursion Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RXRX Profitability Score
Profitability Due Diligence

Recursion Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROIC is Increasing
Exceptional 1-Year Revenue Growth
25/100
Profitability
Score

Recursion Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

RXRX Solvency Score
Solvency Due Diligence

Recursion Pharmaceuticals Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
80/100
Solvency
Score

Recursion Pharmaceuticals Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RXRX Price Targets Summary
Recursion Pharmaceuticals Inc

Wall Street analysts forecast RXRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RXRX is 10.05 USD with a low forecast of 6.06 USD and a high forecast of 12.6 USD.

Lowest
Price Target
6.06 USD
0% Upside
Average
Price Target
10.05 USD
67% Upside
Highest
Price Target
12.6 USD
109% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RXRX?

Click here to dive deeper.

Dividends

Recursion Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RXRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RXRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

RXRX News

Other Videos

See Also

Discover More
What is the Intrinsic Value of one RXRX stock?

The intrinsic value of one RXRX stock under the Base Case scenario is 1.89 USD.

Is RXRX stock undervalued or overvalued?

Compared to the current market price of 6.03 USD, Recursion Pharmaceuticals Inc is Overvalued by 69%.

Back to Top